News
Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to talk about the risks of sitting for too ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...
Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.
A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...
Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...
The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...
A decision is expected in the fourth quarter of 2025.
Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results